Compare Abeona Therapeutics Inc (ABEO) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gigacloud Technology Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Gigacloud Technology Inc trades at $33.46 (market cap $1.23B). The key difference: Gigacloud Technology Inc is far larger — about 3.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GCT | |
|---|---|---|
Market Cap | $373.32M | $1.23B |
Sector | Health | Technology |
52-Week High | $7.23 | $51.80 |
52-Week Low | $4.17 | $20.26 |
Enterprise Value | $228.22M | $1.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GigaCloud Technology (GCT) trades at $34.08, up 2.62% with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats, with Q1 2026 EPS of $1.04 exceeding expectations by 20%, and maintains healthy profitability with a 10.77% net margin. Recent news highlights inclusion in TIME's World's Growth Leaders 2026 list and positive analyst coverage, supporting investor confidence.
Outlook remains positive due to undervaluation (P/E 8.64), growth in European markets, and strategic expansions. Risks include potential fiduciary concerns flagged by shareholders and reliance on large parcel merchandise demand. Analyst consensus is 66.7% buy, with a $56 price target from Seeking Alpha on 2026-06-10 suggesting 64% upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
